A | HUMAN NECESSITIES | |||
HEALTH; LIFE-SAVING; AMUSEMENT | ||||
A61 | MEDICAL OR VETERINARY SCIENCE; HYGIENE | |||
A61P | SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS [7] | |||
Note(s) [2012.01]
| ||||
A61P 1/00 | ||||
A61P 1/02 | • | |||
A61P 1/04 | • for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants [2006.01] | |||
A61P 1/06 | • | |||
A61P 1/08 | • for nausea, cinetosis or vertigo; Antiemetics [2006.01] | |||
A61P 1/10 | • Laxatives [2006.01] | |||
A61P 1/12 | • Antidiarrhoeals [2006.01] | |||
A61P 1/14 | • Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents [2006.01] | |||
A61P 1/16 | • for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics [2006.01] | |||
A61P 1/18 | • for pancreatic disorders, e.g. pancreatic enzymes [2006.01] | |||
A61P 3/00 | ||||
A61P 3/02 | • Nutrients, e.g. vitamins, minerals [2006.01] | |||
A61P 3/04 | • Anorexiants; Antiobesity agents [2006.01] | |||
A61P 3/06 | • Antihyperlipidemics [2006.01] | |||
A61P 3/08 | • | |||
A61P 3/10 | • • for hyperglycaemia, e.g. antidiabetics [2006.01] | |||
A61P 3/12 | • for electrolyte homeostasis [2006.01] | |||
A61P 3/14 | • • for calcium homeostasis (vitamin D A61P 3/02; parathyroid hormones A61P 5/18; calcitonin A61P 5/22; osteoporosis A61P 19/10; bone metastasis A61P 35/04) [2006.01] | |||
A61P 5/00 | ||||
A61P 5/02 | • of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin [2006.01] | |||
A61P 5/04 | • • for decreasing, blocking or antagonising the activity of the hypothalamic hormones [2006.01] | |||
A61P 5/06 | • of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH [2006.01] | |||
A61P 5/08 | • • for decreasing, blocking or antagonising the activity of the anterior pituitary hormones [2006.01] | |||
A61P 5/10 | • of the posterior pituitary hormones, e.g. oxytocin, ADH [2006.01] | |||
A61P 5/12 | • • for decreasing, blocking or antagonising the activity of the posterior pituitary hormones [2006.01] | |||
A61P 5/14 | • of the thyroid hormones, e.g. T3, T4 [2006.01] | |||
A61P 5/16 | • • for decreasing, blocking or antagonising the activity of the thyroid hormones [2006.01] | |||
A61P 5/18 | • of the parathyroid hormones [2006.01] | |||
A61P 5/20 | • • for decreasing, blocking or antagonising the activity of PTH [2006.01] | |||
A61P 5/22 | • • for decreasing, blocking or antagonising the activity of calcitonin [2006.01] | |||
A61P 5/24 | • of the sex hormones [2006.01] | |||
A61P 5/26 | • • Androgens [2006.01] | |||
A61P 5/28 | • • Antiandrogens [2006.01] | |||
A61P 5/30 | • • Oestrogens [2006.01] | |||
A61P 5/32 | • • Antioestrogens [2006.01] | |||
A61P 5/34 | • • Gestagens [2006.01] | |||
A61P 5/36 | • • Antigestagens [2006.01] | |||
A61P 5/38 | • of the suprarenal hormones [2006.01] | |||
A61P 5/40 | • • | |||
A61P 5/42 | • • for decreasing, blocking or antagonising the activity of mineralocorticosteroids [2006.01] | |||
A61P 5/44 | • • | |||
A61P 5/46 | • • for decreasing, blocking or antagonising the activity of glucocorticosteroids [2006.01] | |||
A61P 5/48 | • of the pancreatic hormones [2006.01] | |||
A61P 5/50 | • • for increasing or potentiating the activity of insulin [2006.01] | |||
A61P 7/00 | ||||
A61P 7/02 | • Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors [2006.01] | |||
A61P 7/04 | • Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents [2006.01] | |||
A61P 7/06 | • Antianaemics [2006.01] | |||
A61P 7/08 | • Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04) [2006.01] | |||
A61P 7/10 | • Antioedematous agents; Diuretics [2006.01] | |||
A61P 7/12 | • | |||
A61P 9/00 | ||||
A61P 9/02 | • | |||
A61P 9/04 | • | |||
A61P 9/06 | • Antiarrhythmics [2006.01] | |||
A61P 9/08 | • Vasodilators for multiple indications [2006.01] | |||
A61P 9/10 | • | |||
A61P 9/12 | • Antihypertensives [2006.01] | |||
A61P 9/14 | • | |||
A61P 11/00 | ||||
A61P 11/02 | • Nasal agents, e.g. decongestants [2006.01] | |||
A61P 11/04 | • for throat disorders [2006.01] | |||
A61P 11/06 | • Antiasthmatics [2006.01] | |||
A61P 11/08 | • Bronchodilators [2006.01] | |||
A61P 11/10 | • Expectorants [2006.01] | |||
A61P 11/12 | • Mucolytics [2006.01] | |||
A61P 11/14 | • Antitussive agents [2006.01] | |||
A61P 11/16 | • Central respiratory analeptics [2006.01] | |||
A61P 13/00 | ||||
A61P 13/02 | • of urine or of the urinary tract, e.g. urine acidifiers [2006.01] | |||
A61P 13/04 | • for urolithiasis [2006.01] | |||
A61P 13/06 | • Anti-spasmodics [2006.01] | |||
A61P 13/08 | • of the prostate [2006.01] | |||
A61P 13/10 | • of the bladder [2006.01] | |||
A61P 13/12 | • of the kidneys [2006.01] | |||
A61P 15/00 | ||||
A61P 15/02 | • for disorders of the vagina [2006.01] | |||
A61P 15/04 | • for inducing labour or abortion; Uterotonics [2006.01] | |||
A61P 15/06 | • Antiabortive agents; Labour repressants [2006.01] | |||
A61P 15/08 | • for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis [2006.01] | |||
A61P 15/10 | • for impotence [2006.01] | |||
A61P 15/12 | • for climacteric disorders [2006.01] | |||
A61P 15/14 | • for lactation disorders, e.g. galactorrhoea [2006.01] | |||
A61P 15/16 | • Masculine contraceptives [2006.01] | |||
A61P 15/18 | • Feminine contraceptives [2006.01] | |||
A61P 17/00 | ||||
A61P 17/02 | • for treating wounds, ulcers, burns, scars, keloids, or the like [2006.01] | |||
A61P 17/04 | • Antipruritics [2006.01] | |||
A61P 17/06 | • Antipsoriatics [2006.01] | |||
A61P 17/08 | • Antiseborrheics [2006.01] | |||
A61P 17/10 | • Anti-acne agents [2006.01] | |||
A61P 17/12 | • Keratolytics, e.g. wart or anti-corn preparations [2006.01] | |||
A61P 17/14 | • for baldness or alopecia [2006.01] | |||
A61P 17/16 | • Emollients or protectives, e.g. against radiation [2006.01] | |||
A61P 17/18 | • Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00) [2006.01] | |||
A61P 19/00 | ||||
A61P 19/02 | • for joint disorders, e.g. arthritis, arthrosis [2006.01] | |||
A61P 19/04 | • for non-specific disorders of the connective tissue [2006.01] | |||
A61P 19/06 | • Antigout agents, e.g. antihyperuricemic or uricosuric agents [2006.01] | |||
A61P 19/08 | • for bone diseases, e.g. rachitism, Paget's disease [2006.01] | |||
A61P 19/10 | • • for osteoporosis [2006.01] | |||
A61P 21/00 | ||||
A61P 21/02 | • Muscle relaxants, e.g. for tetanus or cramps [2006.01] | |||
A61P 21/04 | • for myasthenia gravis [2006.01] | |||
A61P 21/06 | • | |||
A61P 23/00 | Anaesthetics [2006.01] | |||
A61P 23/02 | • Local anaesthetics [2006.01] | |||
A61P 25/00 | ||||
A61P 25/02 | • for peripheral neuropathies [2006.01] | |||
A61P 25/04 | • Centrally acting analgesics, e.g. opioids [2006.01] | |||
A61P 25/06 | • Antimigraine agents [2006.01] | |||
A61P 25/08 | • Antiepileptics; Anticonvulsants [2006.01] | |||
A61P 25/10 | • • for petit-mal [2006.01] | |||
A61P 25/12 | • • for grand-mal [2006.01] | |||
A61P 25/14 | • for treating abnormal movements, e.g. chorea, dyskinesia [2006.01] | |||
A61P 25/16 | • • | |||
A61P 25/18 | • | |||
A61P 25/20 | • Hypnotics; Sedatives [2006.01] | |||
A61P 25/22 | • Anxiolytics [2006.01] | |||
A61P 25/24 | • Antidepressants [2006.01] | |||
A61P 25/26 | • Psychostimulants, e.g. nicotine, cocaine [2006.01] | |||
A61P 25/28 | • | |||
A61P 25/30 | • for treating abuse or dependence [2006.01] | |||
A61P 25/32 | • • Alcohol-abuse [2006.01] | |||
A61P 25/34 | • • Tobacco-abuse [2006.01] | |||
A61P 25/36 | • • Opioid-abuse [2006.01] | |||
A61P 27/00 | ||||
A61P 27/02 | • Ophthalmic agents [2006.01] | |||
A61P 27/04 | • • Artificial tears; Irrigation solutions [2006.01] | |||
A61P 27/06 | • • Antiglaucoma agents or miotics [2006.01] | |||
A61P 27/08 | • • Mydriatics or cycloplegics [2006.01] | |||
A61P 27/10 | • • for accommodation disorders, e.g. myopia [2006.01] | |||
A61P 27/12 | • • for cataracts [2006.01] | |||
A61P 27/14 | • • Decongestants or antiallergics [2006.01] | |||
A61P 27/16 | • Otologicals [2006.01] | |||
A61P 29/00 | ||||
A61P 29/02 | • without antiinflammatory effect [2006.01] | |||
A61P 31/00 | Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics [2006.01] | |||
A61P 31/02 | • Local antiseptics [2006.01] | |||
A61P 31/04 | • Antibacterial agents [2006.01] | |||
A61P 31/06 | • • for tuberculosis [2006.01] | |||
A61P 31/08 | • • for leprosy [2006.01] | |||
A61P 31/10 | • Antimycotics [2006.01] | |||
A61P 31/12 | • Antivirals [2006.01] | |||
A61P 31/14 | • • for RNA viruses [2006.01] | |||
A61P 31/16 | • • • for influenza or rhinoviruses [2006.01] | |||
A61P 31/18 | • • • for HIV [2006.01] | |||
A61P 31/20 | • • for DNA viruses [2006.01] | |||
A61P 31/22 | • • • for herpes viruses [2006.01] | |||
A61P 33/00 | Antiparasitic agents [2006.01] | |||
A61P 33/02 | • Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis [2006.01] | |||
A61P 33/04 | • • Amoebicides [2006.01] | |||
A61P 33/06 | • • Antimalarials [2006.01] | |||
A61P 33/08 | • • for Pneumocystis carinii [2006.01] | |||
A61P 33/10 | • Anthelmintics [2006.01] | |||
A61P 33/12 | • • Schistosomicides [2006.01] | |||
A61P 33/14 | • Ectoparasiticides, e.g. scabicides [2006.01] | |||
A61P 35/00 | Antineoplastic agents [2006.01] | |||
A61P 35/02 | • specific for leukemia [2006.01] | |||
A61P 35/04 | • specific for metastasis [2006.01] | |||
A61P 37/00 | ||||
A61P 37/02 | • Immunomodulators [2006.01] | |||
A61P 37/04 | • • Immunostimulants [2006.01] | |||
A61P 37/06 | • • | |||
A61P 37/08 | • Antiallergic agents (antiasthmatic agents A61P 11/06; ophthalmic antiallergics A61P 27/14) [2006.01] | |||
A61P 39/00 | General protective or antinoxious agents [2006.01] | |||
A61P 39/02 | • Antidotes [2006.01] | |||
A61P 39/04 | • Chelating agents [2006.01] | |||
A61P 39/06 | • Free radical scavengers or antioxidants [2006.01] | |||
A61P 41/00 | ||||
A61P 43/00 | ||||
Note(s) [2010.01]
|